Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1385-1394

  Castiglione Gertsch, Monica ^a  

^a International Breast Cancer Study Group   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VOMITING;

EID: 0030905146     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1385     Document Type: Article

References (22)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339:1-15, 71-85, 1992
2. Ludwig Breast Cancer Study Group: Randomized trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1:1256-1260, 1984
3. Speer JF, Petrosky VE, Retsky MW, et al: A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res 44:4124-4130, 1984
4. Gompertz B: On the nature of the function expressive of the law of human mortality and on a new mode of determining the value of life contingencies. Phil Trans R Soc London 115:513-585, 1825
5. Valagussa P, Tancini G, Bonadonna G, et al: Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 58:1411-1417, 1986
6. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
7. Gelber RD, Zelen M: Planning and reporting clinical trials, in Calabresi P, Rosenberg SA, Schein P (eds): Medical Oncology: Basic Principles and Clinical Management of Cancer. New York, NY, Macmillan, 1985, pp 406-425
8. Cox DR: Regression models and life-tables. J R Stat Soc (B) 34:187-220, 1972
9. Hürny C, Bernhard J, Coates A, et al: Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet 347:1279-1284, 1996
10. Wallgren A, Bernier J, Gelber RD, et al: Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. Int J Radiat Oncol Biol Phys 35: 649-659, 1996
11. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, et al: The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 5:717-724, 1994
12. Boccardo F, Rubagotti A, Bruzzi P, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multi-centric Italian study. J Clin Oncol 8:1310-1320, 1990
13. Rivkin SE, Green S, Metch V, et al: Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study. J Clin Oncol 12:2078-2085, 1994
14. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018, 1990
15. Shapiro CL, Henderson IC: Late cardiac effects of adjuvant therapy: Too soon to tell? Ann Oncol 5:196-198, 1994
16. DeCillis A, Anderson S, Wickerham DL, et al: Acute myeloid leukemia (AML) in NSABP B-25. Proc Am Soc Clin Oncol 14:98, 1995 (abstr 92)
17. Levine M, Bramwell V, Bowman D, et al: A clinical trial of intensive CEF versus CMF in premenopausal women with node-positive breast cancer. Proc Am Soc Clin Oncol 14:103, 1995 (abstr 112)
18. Fisher B, Redmond C, Brown A, et al: Adjuvant chemotherapy with and without tamoxifen: Five-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 4:459-471, 1986
19. Osborne CK: Interactions of tamoxifen with cytotoxic chemotherapy for breast cancer, in Jordan VC, (ed): Long Term Tamoxifen for Breast Cancer. Madison, WI, University of Wisconsin, 1994, pp 181-198
20. Wolf DM, Langan-Fahey SM, Parker CP, et al: Investigation of the mechanism of tamoxifen-stimulated breast tumor growth using non-isomerizable analogs of tamoxifen and metabolites. J Natl Cancer Inst 85:806-812, 1993
21. Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320:491-496, 1989
22. Goldhirsch A, Gelber RD, Castiglione M, et al: Present and future projects of the International Breast Cancer Study Group. Cancer 74:1139-1149, 1994